Avelumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AIFA (Italy), AOTMIT (Poland) and DMC (Denmark), among others, recommended or restricted avelumab, while CIPM (Spain) did not recommend it.
Assessment has run over 8.8 years, from 2 Aug 2017 at AWMSG (Wales) to 1 Jun 2026 at DMC (Denmark).
NYE METODER (Norway) changed its position: not recommended on 30 Aug 2020, recommended by 29 Aug 2021, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for avelumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 8 of 42 records date from 2023 or later.
The programme is broad: 12 distinct indication wordings are recorded for avelumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
8 of these 42 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess avelumab, on 2 Aug 2017; DMC (Denmark) did not open a file until 1 Jun 2026 — an unusually long tail of 8.8 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 9 years in total.
11 of the 13 agencies here assessed avelumab more than once, PBAC (Australia) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
avelumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for avelumab reads 22 recommended, 7 not recommended, 5 restricted and 3 deferred to NICE, with 5 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 1 Jun 2026 | Urotelialt karcinom | Anbefalet | source |
| NICE (England) | 8 Jan 2026 | NICE TA1120 | published appraisal | source |
| PBAC (Australia) | 2024 | Stage IV clear cell variant renal cell carcinoma | The PBAC rescinded the March 2021 recommendation for avelumab. | source |
| HAS (France) | 4 Oct 2023 | Re-assessment following post-listing study results | SMR substantial · ASMR IV | source |
| AIFA (Italy) | 24 Sep 2018 | indicato in monoterapia per il trattamento di pazienti adulti affetti da carcinoma a cellule di Merkel (Merkel Cell Carc… | conditionally innovative | source |
37 further decisions for avelumab, across 13 agencies, are not shown here. They include the most recent record on file, 1 Jun 2026 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 25 further source documents.
Related molecules
- cabozantinib — divergent outcome (recommended vs not recommended) on a shared indication
- pembrolizumab — same ATC class L01F — Antineoplastics
- nivolumab — same ATC class L01F — Antineoplastics
- daratumumab — same ATC class L01F — Antineoplastics
- rituximab — same ATC class L01F — Antineoplastics
- bevacizumab — same ATC class L01F — Antineoplastics
Coverage: 42 decisions for avelumab from 13 agencies, 2017 to 2026. Data to 7 Sep 2026. ATC class L01F — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.